Dimethyl fumarate Polpharma Den europeiske union - norsk - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Mifepristone Linepharma 200 mg Norge - norsk - Statens legemiddelverk

mifepristone linepharma 200 mg

amring - mifepriston - tablett - 200 mg

Sibnayal Den europeiske union - norsk - EMA (European Medicines Agency)

sibnayal

advicenne s.a. - potassium citrate monohydrated, potassium hydrogen carbonate - acidosis, renal tubular - mineral supplements - sibnayal is indicated for the treatment of distal renal tubular acidosis (drta) in adults, adolescents and children aged one year and older.

Dimethyl fumarate Neuraxpharm Den europeiske union - norsk - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - dimetylfumarat - multippel sklerose, relapsing-remitting - immunsuppressive - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Paracetamol Norfri 500 mg Norge - norsk - Statens legemiddelverk

paracetamol norfri 500 mg

evolan pharma ab - paracetamol - brusetablett - 500 mg

Zutectra Den europeiske union - norsk - EMA (European Medicines Agency)

zutectra

biotest pharma gmbh - human hepatitis b immunoglobulin - immunization, passive; hepatitis b; liver transplantation - immune sera og immunglobuliner, - forebygging av hepatitt b-virus (hbv) re-infeksjon hos hbsag og hbv-dna-negative voksne pasienter minst en uke etter levertransplantasjon for hepatitt b-indusert leversvikt. hbv-dna-negativ status bør bekreftes i løpet av de siste 3 månedene før olt. pasienter bør være hbsag-negative før behandlingsstart. samtidig bruk av tilstrekkelig virostatic agenter bør betraktes som standard av hepatitt b re-infeksjon prophylaxis.

Ranivisio Den europeiske union - norsk - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Øyemidler - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Dimethyl fumarate Sandoz 240 mg Norge - norsk - Statens legemiddelverk

dimethyl fumarate sandoz 240 mg

sandoz a/s - dimetylfumarat - enterokapsel, hard - 240 mg

Dimethyl fumarate Sandoz 120 mg Norge - norsk - Statens legemiddelverk

dimethyl fumarate sandoz 120 mg

sandoz a/s - dimetylfumarat - enterokapsel, hard - 120 mg

Allopurinol Orion 300 mg Norge - norsk - Statens legemiddelverk

allopurinol orion 300 mg

orion corporation - espoo - allopurinol - tablett - 300 mg